Summit Therapeutics (SMMT) has drawn intense attention after its stock dropped sharply following updates that its key Phase III ivonescimab trial will continue without an early efficacy signal, alongside wider first quarter losses and a flagged going concern risk.

The latest Q1 loss and going concern warning have triggered a sharp reset in sentiment, with a 1-day share price return of -24.91% and a 7-day share price return of -27.15%. This has occurred even though the 3-year total shareholder return is around 7x and the 5-year total shareholder return remains strongly positive.

If Summit's recent volatility has you thinking about diversification, it could be a good moment to scan other oncology and biotech ideas through a focused healthcare AI stock screener such as 33 healthcare AI stocks

With the stock down sharply, yet still showing a multiyear gain and trading at a large implied discount to some analyst targets, you have to ask: is this a reset that creates an opening, or is the market already factoring in whatever future growth proves realistic?

Most Popular Narrative: 44.8% Undervalued

Summit Therapeutics last closed at $16.12, while the most widely followed narrative implies a fair value of about $29.18, framing the recent selloff against a much higher long term earnings roadmap.

The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.

Want to see how a single asset, a crowded trial schedule, and ambitious margin assumptions all feed into that fair value gap? The narrative leans heavily on rapid revenue build, a sharp turn toward profitability, and a future earnings multiple that assumes real staying power.

Result: Fair Value of $29.18 (UNDERVALUED)

However, this hinges on ivonescimab clearing tough regulatory hurdles and on Summit managing heavy R&D spending without current product revenue turning into a longer term funding squeeze.

Another View: Expensive On Book Value

The narrative points to a large discount to fair value, but the picture changes when you look at the P/B ratio. Summit Therapeutics trades around 19x book value, compared with about 2.3x for the US Biotechs industry and 13.3x for peers. This raises a clear question: how much optimism is already priced in?

Compared with those industry and peer benchmarks, the current P/B suggests investors are paying a steep premium for future outcomes that still depend on a single lead asset and upcoming trial and regulatory milestones. It is worth asking whether that premium leaves enough room for error or surprise.

Next Steps

Given the mixed sentiment around Summit's valuation and risk profile, it makes sense to look at the full picture and decide quickly where you stand using 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Summit feels too concentrated, do not sit on the sidelines. Broaden your watchlist now so you are not relying on a single story.

• Target potential mispricings by scanning 49 high quality undervalued stocks that pair solid fundamentals with what could be more attractive market expectations.
• Strengthen your income focus by reviewing 13 dividend fortresses that combine higher yields with an emphasis on resilience.
• Dial down volatility by checking 72 resilient stocks with low risk scores designed for investors who want steadier balance sheets and fewer unpleasant surprises.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.